FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2566163406> ?p ?o ?g. }

• W2566163406 endingPage "4220" @default.
• W2566163406 startingPage "4220" @default.
• W2566163406 abstract "Abstract Introduction: Four families are reported to have hereditary thrombocythemia (HT) with a mutation in TPO. Their clinical manifestation is essentially thrombocytosis without leukemia. CML is one of myeloproliferative disorders, and shows leukocytosis and thrombocytosis associated with a proliferation of malignant clone originated from a hematopoietic stem cell (HSC). The incidence of CML is about 5 per 100,000 in Japan. Mutations of cytokine receptor including c-kit, flt-3 and G-CSF receptor are reported as a cause of AML. Especially flt-3 abnormalities are found in about 20% of AML. However, abnormality of c-mpl or TPO is not reported as a cause of leukemia. In this paper, we analyzed a CML case with novel point mutation in the TPO who still had thrombocytosis after cytogenetic complete response. Case: Japanese, 35 y.o., male, complained leukocytosis. He had a family history of thrombocytosis in 4 individuals over 3 generations. A physical examination revealed a moderate splenomegaly. Laboratory tests at the time of diagnosis were as follows; WBC 141,000/μl (blast 1.8%, promyelo 2.4%, myelo 20.0%, meta 8.2%, stab 24.2%, seg 22.2%, immature eosinophils 1.8%, eosinophil 3.6%, immature basophils 0.4%, basophils 10.4%, mono 1.0%, lymphocytes 4.0%, erythroblast 3%), PLT 641,000/μl and NAP score 53 (nl; 156–271). Bone marrow showed hypercellularity with the increased megakaryocytes(Meg), bcr-abl fusion mRNA positive, Ph1 chromosome positive. After 5 months treatment with STI571, most of clinical findings including karyotype and fusion mRNA turned to be normal, but thrombocyte(PLT) still showed more than 1,000,000/μl. At this time, serum TPO concentration was 8.14 f mole/ml (nl; 0.40 +/− 0.28 f mole/ml, mean +/− SD). Genetic analysis of TPO revealed novel point mutation at splicing donor site of 3′-end of the exon3. A point mutation at splicing donor site is reported to cause an exon-skipping and intron-retention, which induce a malfunction of a suppressive post-transcriptional and translational regulation, and consequent high-level expression of functional TPO protein. Discussion: TPO was cloned as a c-mpl ligand, which leads to the production of PLTs. Its receptor is a c-mpl proto-oncogene product, which is expressed not only in Meg, but also in HSC. Thus, TPO can stimulate HSC. The c-mpl transgenic mice are reported to have the increased Meg, its committed progenitor and PLT. Knockout mice of TPO presented not only the decreased Meg, but also multi-lineage committed progenitors. Thus, a modulation of c-mpl or its ligand function affects on both Meg and HSC. The c-mpl was cloned as a cellular homolog of a viral oncogene, v-mpl of myeloproliferative leukemia virus (MPL). The MPL causes myeloproliferative leukemia syndrome through v-mpl function in mice. Since v-mpl and c-mpl indicate high homology, it is possible that abnormal c-mpl function causes v-mpl like response. Through continuous stimulation of c-mpl signal, high TPO concentration may have induced a malignant transformation of HSC or supported a survival of an immature malignant clone in the present case. Improvement of thrombocytosis in CML is one of hematological responses to an anti-CML treatment such as STI571. In such a case who had good response other than thrombocytosis, an existence of HT might be considered. On the other hand, during following up HT family, occurrence of CML should be noted." @default.
• W2566163406 created "2017-01-06" @default.
• W2566163406 creator A5002986053 @default.
• W2566163406 creator A5016801438 @default.
• W2566163406 creator A5031116384 @default.
• W2566163406 creator A5044209012 @default.
• W2566163406 date "2004-11-16" @default.
• W2566163406 modified "2023-09-30" @default.
• W2566163406 title "CML Developed in a Japanese Family Transmitting a Novel Point Mutation in the Thrombopoietin Gene(TPO)." @default.
• W2566163406 doi "https://doi.org/10.1182/blood.v104.11.4220.4220" @default.
• W2566163406 hasPublicationYear "2004" @default.
• W2566163406 type Work @default.
• W2566163406 sameAs 2566163406 @default.
• W2566163406 citedByCount "1" @default.
• W2566163406 countsByYear W25661634062013 @default.
• W2566163406 crossrefType "journal-article" @default.
• W2566163406 hasAuthorship W2566163406A5002986053 @default.
• W2566163406 hasAuthorship W2566163406A5016801438 @default.
• W2566163406 hasAuthorship W2566163406A5031116384 @default.
• W2566163406 hasAuthorship W2566163406A5044209012 @default.
• W2566163406 hasConcept C109159458 @default.
• W2566163406 hasConcept C126322002 @default.
• W2566163406 hasConcept C203014093 @default.
• W2566163406 hasConcept C2777863708 @default.
• W2566163406 hasConcept C2777918643 @default.
• W2566163406 hasConcept C2778461978 @default.
• W2566163406 hasConcept C2778713057 @default.
• W2566163406 hasConcept C2778837598 @default.
• W2566163406 hasConcept C2778923028 @default.
• W2566163406 hasConcept C2779705218 @default.
• W2566163406 hasConcept C2779788118 @default.
• W2566163406 hasConcept C2780007613 @default.
• W2566163406 hasConcept C2781057849 @default.
• W2566163406 hasConcept C28328180 @default.
• W2566163406 hasConcept C2910274570 @default.
• W2566163406 hasConcept C54355233 @default.
• W2566163406 hasConcept C71924100 @default.
• W2566163406 hasConcept C86803240 @default.
• W2566163406 hasConcept C89560881 @default.
• W2566163406 hasConceptScore W2566163406C109159458 @default.
• W2566163406 hasConceptScore W2566163406C126322002 @default.
• W2566163406 hasConceptScore W2566163406C203014093 @default.
• W2566163406 hasConceptScore W2566163406C2777863708 @default.
• W2566163406 hasConceptScore W2566163406C2777918643 @default.
• W2566163406 hasConceptScore W2566163406C2778461978 @default.
• W2566163406 hasConceptScore W2566163406C2778713057 @default.
• W2566163406 hasConceptScore W2566163406C2778837598 @default.
• W2566163406 hasConceptScore W2566163406C2778923028 @default.
• W2566163406 hasConceptScore W2566163406C2779705218 @default.
• W2566163406 hasConceptScore W2566163406C2779788118 @default.
• W2566163406 hasConceptScore W2566163406C2780007613 @default.
• W2566163406 hasConceptScore W2566163406C2781057849 @default.
• W2566163406 hasConceptScore W2566163406C28328180 @default.
• W2566163406 hasConceptScore W2566163406C2910274570 @default.
• W2566163406 hasConceptScore W2566163406C54355233 @default.
• W2566163406 hasConceptScore W2566163406C71924100 @default.
• W2566163406 hasConceptScore W2566163406C86803240 @default.
• W2566163406 hasConceptScore W2566163406C89560881 @default.
• W2566163406 hasIssue "11" @default.
• W2566163406 hasLocation W25661634061 @default.
• W2566163406 hasOpenAccess W2566163406 @default.
• W2566163406 hasPrimaryLocation W25661634061 @default.
• W2566163406 hasRelatedWork W1996760460 @default.
• W2566163406 hasRelatedWork W2045433152 @default.
• W2566163406 hasRelatedWork W2045908279 @default.
• W2566163406 hasRelatedWork W2052172841 @default.
• W2566163406 hasRelatedWork W2065837829 @default.
• W2566163406 hasRelatedWork W2553331837 @default.
• W2566163406 hasRelatedWork W2562290387 @default.
• W2566163406 hasRelatedWork W2566163406 @default.
• W2566163406 hasRelatedWork W2950975533 @default.
• W2566163406 hasRelatedWork W654799503 @default.
• W2566163406 hasVolume "104" @default.
• W2566163406 isParatext "false" @default.
• W2566163406 isRetracted "false" @default.
• W2566163406 magId "2566163406" @default.
• W2566163406 workType "article" @default.